Atea Pharmaceuticals Inc (AVIR)
3.67
-0.05
(-1.34%)
USD |
NASDAQ |
Apr 22, 16:00
3.67
0.00 (0.00%)
After-Hours: 20:00
Atea Pharmaceuticals Free Cash Flow (Quarterly): -21.83M for Dec. 31, 2023
Free Cash Flow (Quarterly) Chart
Historical Free Cash Flow (Quarterly) Data
| Date | Value |
|---|---|
| December 31, 2023 | -21.83M |
| September 30, 2023 | -17.59M |
| June 30, 2023 | -16.12M |
| March 31, 2023 | -29.85M |
| December 31, 2022 | -21.54M |
| September 30, 2022 | -21.26M |
| June 30, 2022 | -21.06M |
| March 31, 2022 | -59.05M |
| Date | Value |
|---|---|
| December 31, 2021 | -75.42M |
| September 30, 2021 | 22.60M |
| June 30, 2021 | -17.35M |
| March 31, 2021 | -16.84M |
| December 31, 2020 | 318.52M |
| September 30, 2020 | -9.496M |
| June 30, 2020 | -7.804M |
| March 31, 2020 | -4.508M |
Free Cash Flow Definition
Free cash flow measures the amount of cash left over from a time period after all operational and working capital payments are made. Free cash flow is an important metric because it allows you to view the amount actual cash is available to the company. Free cash flow is also commonly used in valuation calculations like the discounted cash flow valuation model.
Free Cash Flow (Quarterly) Range, Past 5 Years
-75.42M
Minimum
Dec 2021
318.52M
Maximum
Dec 2020
0.0864M
Average
-17.47M
Median
Free Cash Flow (Quarterly) Benchmarks
| CEL-SCI Corp | -4.953M |
| AIM ImmunoTech Inc | -9.956M |
| IGC Pharma Inc | -1.674M |
| NovaBay Pharmaceuticals Inc | -0.316M |
| Protalix BioTherapeutics Inc | 3.345M |